References
- Chlebowski R, Schwartz AG, Wakelee H, et al Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243–51
- Losordo DW, Isner JM. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 2001;21:6–12
- Raso MG, Behrens C, Herynk MH, et al Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009;15:5359–68
- Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol 2009;305:21
- Ali G, Donati V, Loggini B, et al Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. Hum Pathol 2008;39:1465–73
- Rodriguez C, Spencer Feigelson H, Deka A, et al Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 2008;17:655–60
- Ramnath N, Menezes RJ, Loewen G, et al Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case control study. Oncology 2007;73:305–10
- Parker WH, Broder MS, Chang E, et al Ovarian conservation at the time of hysterectomy and long-term health outcomes on the Nurses' Health Study. Obstet Gynecol 2009;113:1027–37
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–11
- Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804